Comparative Pharmacology
Head-to-head clinical analysis: CHLORMERODRIN HG 197 versus IODOHIPPURATE SODIUM I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORMERODRIN HG 197 versus IODOHIPPURATE SODIUM I 131.
CHLORMERODRIN HG 197 vs IODOHIPPURATE SODIUM I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radioactive mercury isotope that emits gamma rays; distributes in renal parenchyma, allowing scintigraphic imaging of kidneys. The mercury moiety binds to sulfhydryl groups in renal tubules, concentrating in functioning renal tissue.
Iodohippurate sodium I 131 is a radioactive diagnostic agent that is actively transported by the renal tubules, allowing imaging of renal morphology and function. The iodine-131 emits gamma radiation, enabling scintigraphic evaluation of renal blood flow, tubular secretion, and excretion.
Chlormerodrin Hg 197 is administered intravenously as a single dose of 10 µCi (0.37 MBq) for renal imaging. The typical adult dose is 10-30 µCi (0.37-1.11 MBq) IV.
Adult: 5-30 microcuries (0.185-1.11 MBq) intravenously for renal function studies.
None Documented
None Documented
Terminal elimination half-life approximately 3 days (72 hours) in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 60 minutes in patients with normal renal function. In renal impairment, half-life may be prolonged up to several hours, correlating with reduced clearance.
Renal: >90% of absorbed dose excreted in urine within 24 hours; biliary/fecal: <5%.
Primarily renal; >90% of administered dose excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Fecal excretion <2%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical